OBJECTIVE: To test the hypothesis that monogenic neuropathies such as Charcot-Marie-Tooth disease (CMT) contribute to frequent but often unexplained neuropathies in the elderly, we performed genetic analysis of 230 patients with unexplained axonal neuropathies and disease onset ≥35 years. METHODS: We recruited patients, collected clinical data, and conducted whole-exome sequencing (WES; n = 126) and MME single-gene sequencing (n = 104). We further queried WES repositories for MME variants and measured blood levels of the MME-encoded protein neprilysin. RESULTS: In the WES cohort, the overall detection rate for assumed disease-causing variants in genes for CMT or other conditions associated with neuropathies was 18.3% (familial cases 26.4%, apparently sporadic cases 12.3%). MME was most frequently involved and accounted for 34.8% of genetically solved cases. The relevance of MME for late-onset neuropathies was further supported by detection of a comparable proportion of cases in an independent patient sample, preponderance of MME variants among patients compared to population frequencies, retrieval of additional late-onset neuropathy patients with MME variants from WES repositories, and low neprilysin levels in patients' blood samples. Transmission of MME variants was often consistent with an incompletely penetrant autosomal-dominant trait and less frequently with autosomal-recessive inheritance. CONCLUSIONS: A detectable fraction of unexplained late-onset axonal neuropathies is genetically determined, by variants in either CMT genes or genes involved in other conditions that affect the peripheral nerves and can mimic a CMT phenotype. MME variants can act as completely penetrant recessive alleles but also confer dominantly inherited susceptibility to axonal neuropathies in an aging population.

From the Friedrich Baur Institute Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Germany

Komentář v

Neurology. 2020 Dec 15;95(24):1071-1073. doi: 10.1212/WNL.0000000000011133. PubMed

Zobrazit více v PubMed

Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997;62:310–318. PubMed PMC

Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol 2016;263:1903–1910. PubMed

Mathis S, Vallat JM, Ingrand P, Neau JP, Bouche P. Causes of neuropathy in the elderly: a retrospective study with 785 patients. Eur Geriatr Med 2015;6:114–118.

Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 2016;87:1892–1898. PubMed

Auer-Grumbach M, Strasser-Fuchs S, Robl T, Windpassinger C, Wagner K. Late onset Charcot-Marie-Tooth 2 syndrome caused by two novel mutations in the MPZ gene. Neurology 2003;61:1435–1437. PubMed

Chung KW, Kim SB, Park KD, et al. . Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 2006;129:2103–2118. PubMed

Nicolaou P, Cianchetti C, Minaidou A, et al. . A novel LRSAM1 mutation is associated with autosomal dominant axonal Charcot-Marie-Tooth disease. Eur J Hum Genet 2013;21:190–194. PubMed PMC

Oberstadt M, Mitter D, Classen J, Baum P. Late onset dHMN II caused by c.404C>G mutation in HSPB1 gene. J Peripher Nerv Syst 2016;21:111–113. PubMed

Gonzalez M, McLaughlin H, Houlden H, et al. . Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry 2013;84:1247–1249. PubMed PMC

Higuchi Y, Hashiguchi A, Yuan J, et al. . Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. Ann Neurol 2016;79:659–672. PubMed PMC

Depondt C, Donatello S, Rai M, et al. . MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43). Neurol Genet 2016;2:e94. PubMed PMC

Auer-Grumbach M, Toegel S, Schabhuttl M, et al. . Rare variants in MME, encoding metalloprotease neprilysin, are linked to late-onset autosomal-dominant axonal polyneuropathies. Am J Hum Genet 2016;99:607–623. PubMed PMC

Lassuthova P, Safka Brozkova D, Krutova M, et al. . Improving diagnosis of inherited peripheral neuropathies through gene panel analysis. Orphanet J Rare Dis 2016;11:118. PubMed PMC

Lek M, Karczewski KJ, Minikel EV, et al. . Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285–291. PubMed PMC

Engeholm M, Sekler J, Schondorf DC, et al. . A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. BMC Neurol 2014;14:118. PubMed PMC

Peeters K, Palaima P, Pelayo-Negro AL, et al. . Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1. Ann Neurol 2016;80:823–833. PubMed

Hakonen JE, Sorrentino V, Avagliano Trezza R, et al. . LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet 2017;26:2034–2041. PubMed

Hu B, Arpag S, Zuchner S, Li J. A novel missense mutation of CMT2P alters transcription machinery. Ann Neurol 2016;80:834–845. PubMed PMC

Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086–1097. PubMed

Llewellyn DH, Smyth SJ, Elder GH, Hutchesson AC, Rattenbury JM, Smith MF. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet 1992;89:97–98. PubMed

Kazamel M, Sorenson EJ, McEvoy KM, et al. . Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve 2016;54:94–99. PubMed

Adzhubei IA, Schmidt S, Peshkin L, et al. . A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–249. PubMed PMC

Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073–1081. PubMed

Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310–315. PubMed PMC

Lupo V, Frasquet M, Sanchez-Monteagudo A, et al. . Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations. J Med Genet 2018;55:814–823. PubMed

Wang W, Wang C, Dawson DB, et al. . Target-enrichment sequencing and copy number evaluation in inherited polyneuropathy. Neurology 2016;86:1762–1771. PubMed PMC

Kerschen P, Plante-Bordeneuve V. Current and future treatment approaches in transthyretin familial amyloid polyneuropathy. Curr Treat Option Neurol 2016;18:53. PubMed

Wikberg A, Andersson C, Lithner F. Signs of neuropathy in the lower legs and feet of patients with acute intermittent porphyria. J Intern Med 2000;248:27–32. PubMed

Fontanellas A, Avila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med 2016;18:e17. PubMed

Gonzalez MA, Feely SM, Speziani F, et al. . A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. Brain 014;137:2897–2902. PubMed PMC

Liesa M, Palacin M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev 2009;89:799–845. PubMed

Polke JM, Laura M, Pareyson D, et al. . Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 2011;77:168–173. PubMed PMC

Boncoraglio A, Minoia M, Carra S. The family of mammalian small heat shock proteins (HSPBs): implications in protein deposit diseases and motor neuropathies. Int J Biochem Cell Biol 2012;44:1657–1669. PubMed

Houlden H, Laura M, Wavrant-De Vrieze F, Blake J, Wood N, Reilly MM. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 2008;71:1660–1668. PubMed

Guernsey DL, Jiang H, Bedard K, et al. . Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease. Plos Genet 2010;6:e1001081. PubMed PMC

Weterman MA, Sorrentino V, Kasher PR, et al. . A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum Mol Genet 2012;21:358–370. PubMed PMC

Genis D, Ortega-Cubero S, San Nicolas H, et al. . Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48). Neurology 2018;91:e1988-e98. PubMed

Shi Y, Wang J, Li JD, et al. . Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One 2013;8:e81884. PubMed PMC

Sanchez-Ferrero E, Coto E, Beetz C, et al. . SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet 2013;83:257–262. PubMed

Cummings BB, Marshall JL, Tukiainen T, et al. . Improving genetic diagnosis in mendelian disease with transcriptome sequencing. Sci Transl Med 2017;9:eaal5209. PubMed PMC

Holmgren G, Costa PM, Andersson C, et al. . Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351–354. PubMed PMC

Plante-Bordeneuve V, Carayol J, Ferreira A, et al. . Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120. PubMed PMC

Hong D, Fang P, Yao S, et al. . Variants in MME are associated with autosomal-recessive distal hereditary motor neuropathy. Ann Clin Transl Neurol 2019;6:1728-1738. PubMed PMC

Nam DE, Yoo DH, Choi SS, Choi BO, Chung KW. Wide phenotypic spectrum in axonal Charcot-Marie-Tooth neuropathy type 2 patients with KIF5A mutations. Genes Genomics 2018;40:77–84. PubMed

Nicolas A, Kenna KP, Renton AE, et al. . Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 2018;97:1268–1283 e6. PubMed PMC

Madani R, Poirier R, Wolfer DP, et al. . Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 2006;84:1871–1878. PubMed

Mohajeri MH, Wolfer DP. Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis. Neurochem Res 2009;34:717–726. PubMed

Grimmer T, Goldhardt O, Yakushev I, et al. . Associations of neprilysin activity in CSF with biomarkers for Alzheimer's disease. Neurodegener Dis 2019;19:43–50. PubMed

Solomon SD, Claggett B, McMurray JJ, Hernandez AF, Fonarow GC. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur J Heart Fail 2016;18:1238–1243. PubMed

Campbell DJ. Long-term neprilysin inhibition: implications for ARNIs. Nat Rev Cardiol 2017;14:171–186. PubMed